Table 2.
Breakdown of patients on chemotherapy in relation to the disease subtype
| ATL subtype (n = 14) | n (%) | Therapy | |
|---|---|---|---|
| mLSG15/-L n (%) |
CHOP/-La
n (%) |
||
| Acute | 10 (71) | 6 (43) | 4 (29) |
| Lymphoma | 1 (7) | 1 (7) | 0 (0) |
| Chronic | 3 (21) | 2 (14) | 1 (7) |
| PTCL subtype (n = 11) | n (%) | Therapy | |
|---|---|---|---|
| CHOP n (%) |
CHOP-La
n (%) |
||
| AITL | 5 (45) | 1 (9) | 4 (36) |
| PTCL-NOS | 3 (27) | 1 (9) | 2 (18) |
| ALCL ALK- | 1 (9) | 1 (9) | 0 (0) |
| EATL | 1 (9) | 0 (0) | 1 (9) |
| SPTCL | 1 (9) | 0 (0) | 1 (9) |
AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, ATL adult T-cell leukemia–lymphoma, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone; CHOP-L CHOP-like regimen, CHOP/-L CHOP or CHOP-like regimen, EATL enteropathy-associated T-cell lymphoma, mLSG15 vincristine, cyclophosphamide, doxorubicin, prednisone and doxorubicin, ranimustine, prednisone and vindesine, etoposide, carboplatin, prednisone, mLSG15/-L mLSG15 or mLSG15-like regimen, NOS not otherwise specified, PTCL peripheral T-cell lymphoma, SPTCL subcutaneous panniculitis-like T-cell lymphoma
aTHP-COP, vincristine, pirarubicin, cyclophosphamide, and prednisone